NCT02262325View on ClinicalTrials.gov

Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 8, 2015

Primary Completion Date

April 15, 2024

Study Completion Date

April 15, 2024

Conditions
Recurrent Non-small Cell Lung CancerStage IIA Non-small Cell Lung CancerStage IIB Non-small Cell Lung CancerStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung Cancer
Interventions
RADIATION

hypofractionated radiation therapy

Radiation boost in week 1 (days 1-5)

DRUG

cisplatin

Given IV

DRUG

etoposide

Given IV

RADIATION

3-dimensional conformal radiation therapy

Undergo 3-dimensional conformal radiation therapy

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT02262325 - Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery | Biotech Hunter | Biotech Hunter